Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital.
Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital.
Biolojic Design Ltd. has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd., for TEV‘325 (TEV-56308, formerly BD-9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP) for autoimmune disease
